Nick and Fiona talk to Greig Pickhaver about the new SBS show Secrets Of Our Cities about the history of Australian ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine ...

Fintel reports that on October 31, 2025, Needham reiterated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy recommendation. Analyst Price Forecast Suggests 8.29% Upside As of October 30, 2025, ...

For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option.

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

Continued strength in the HIV portfolio driven by flagship drugs Biktarvy and Descovy, bolstered by FDA approval of long-acting injectable PrEP medication, lenacapavir (Yeztugo). Growth in HIV sales ...

The MarketWatch News Department was not involved in the creation of this content. Groups welcome reversal of Gilead's price gouging decision that would have resulted in fewer people with HIV getting ...

MOUNT GILEAD — Mount Gilead's football team likes it routine. "They are programed to the point of where I’m almost worried about a bye," MG football coach Mike Reid said. "They are very programed. One ...

CARDINGTON — Mount Gilead won nine games in a football season for just the second time in school history. It also earned a spot into the playoffs for the second time for the program. So the team ...